368 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase http://www.zacks.com/stock/news/610241/teva-teva-q3-earnings-miss-stock-up-on-guidance-increase?cid=CS-ZC-FT-analyst_blog|earnings_article-610241 Nov 08, 2019 - Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.
Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products http://www.zacks.com/stock/news/610160/pharma-stock-roundup-agn-nvo-q3-earnings-fda-nod-to-sny-nvs-products?cid=CS-ZC-FT-analyst_blog|stock_roundup-610160 Nov 08, 2019 - Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.
Allergan (AGN) Q3 Earnings Meet Estimates http://www.zacks.com/stock/news/604109/allergan-agn-q3-earnings-meet-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-604109 Nov 05, 2019 - Allergan (AGN) delivered earnings and revenue surprises of 0.00% and 4.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View http://www.zacks.com/stock/news/604652/allergan-agn-meets-q3-earnings-estimates-ups-19-sales-view?cid=CS-ZC-FT-analyst_blog|earnings_article-604652 Nov 05, 2019 - Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More http://www.zacks.com/stock/news/602683/drug-biotech-stocks-nov-5-earnings-roster-agn-regn-more?cid=CS-ZC-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-602683 Nov 04, 2019 - Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.
Allergan (AGN) Hits 52-Week High, Can the Run Continue? http://www.zacks.com/stock/news/602389/allergan-agn-hits-52-week-high-can-the-run-continue?cid=CS-ZC-FT-52_week_high-602389 Nov 04, 2019 - Allergan (AGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
WIll Allergan (AGN) Beat Estimates This Earnings Season? http://www.zacks.com/stock/news/598369/will-allergan-agn-beat-estimates-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-598369 Nov 01, 2019 - Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q3 as loss of exclusivity of several products hurts sales.
Is a Beat in the Cards for Mallinckrodt (MNK) in Q3 Earnings? http://www.zacks.com/stock/news/598368/is-a-beat-in-the-cards-for-mallinckrodt-mnk-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-598368 Nov 01, 2019 - Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q3 results.
Ironwood (IRWD) Beats on Q3 Earnings & Revenues, Ups '19 View http://www.zacks.com/stock/news/598331/ironwood-irwd-beats-on-q3-earnings-revenues-ups-19-view?cid=CS-ZC-FT-analyst_blog|earnings_article-598331 Nov 01, 2019 - Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter as well.
Is a Beat in the Cards for Regeneron (REGN) Q3 Earnings? http://www.zacks.com/stock/news/598310/is-a-beat-in-the-cards-for-regeneron-regn-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-598310 Nov 01, 2019 - Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports third-quarter 2019 results.

Pages: 123456...37

Page 1>